Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
06 2020
Historique:
received: 30 05 2019
revised: 07 02 2020
accepted: 18 03 2020
pubmed: 23 3 2020
medline: 1 10 2021
entrez: 23 3 2020
Statut: ppublish

Résumé

MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We used modestly elevated expression of human MYC, driven from the

Identifiants

pubmed: 32200350
pii: 2159-8290.CD-19-0620
doi: 10.1158/2159-8290.CD-19-0620
pmc: PMC7611248
mid: EMS128842
doi:

Substances chimiques

Interferon Type I 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

872-887

Subventions

Organisme : Wellcome Trust
ID : 105614/Z/14/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A17196
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A21139
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A23983
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 105614
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A25142
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Worldwide Cancer Research
ID : 15-0279
Pays : United Kingdom

Informations de copyright

©2020 American Association for Cancer Research.

Références

PLoS Pathog. 2018 May 31;14(5):e1007104
pubmed: 29851983
Nature. 2016 Mar 3;531(7592):110-3
pubmed: 26909577
Trends Cancer. 2016 Jan;2(1):1-3
pubmed: 28741497
Nat Rev Immunol. 2018 Nov;18(11):671-688
pubmed: 30209347
Clin Cancer Res. 2018 Jul 15;24(14):3299-3308
pubmed: 29618619
Nature. 2018 Feb 1;554(7690):62-68
pubmed: 29364867
Mol Cell Biol. 1997 Jan;17(1):100-14
pubmed: 8972190
J Neuroinflammation. 2019 Dec 29;16(1):282
pubmed: 31884963
Immunity. 2010 Dec 14;33(6):917-28
pubmed: 21167753
Nat Commun. 2018 Nov 23;9(1):4945
pubmed: 30470748
Nat Commun. 2017 Nov 23;8(1):1728
pubmed: 29170413
Cancer Cell. 2016 Jan 11;29(1):75-89
pubmed: 26725216
Cancer Discov. 2020 Apr;10(4):608-625
pubmed: 32046984
Cell. 2014 Jul 3;158(1):185-197
pubmed: 24954535
Sci Rep. 2017 May 12;7(1):1837
pubmed: 28500323
Cancer Cell. 2008 Dec 9;14(6):447-57
pubmed: 19061836
Nucleic Acids Res. 2018 Jan 4;46(D1):D776-D780
pubmed: 29077937
Cancer Res. 1985 Aug;45(8):3735-41
pubmed: 3893689
Genes Dev. 2014 Jan 1;28(1):85-97
pubmed: 24395249
Immunity. 2000 Nov;13(5):715-25
pubmed: 11114383
Mech Dev. 2003 Jan;120(1):65-80
pubmed: 12490297
J Exp Med. 2019 Mar 4;216(3):621-637
pubmed: 30723095
Development. 2002 May;129(10):2447-57
pubmed: 11973276
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Cancer Discov. 2020 Apr;10(4):588-607
pubmed: 31941709
Cancer Res. 2020 Apr 1;80(7):1414-1427
pubmed: 32029551
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51
pubmed: 20018721
Mod Pathol. 2002 Apr;15(4):462-9
pubmed: 11950922
Br J Cancer. 2015 Jul 28;113(3):365-71
pubmed: 26151455
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Crit Rev Immunol. 2017;37(2-6):439-462
pubmed: 29773029
Nat Commun. 2019 Jul 2;10(1):2921
pubmed: 31266943
Nature. 2014 Jul 24;511(7510):483-7
pubmed: 25043018
Elife. 2016 Jul 27;5:
pubmed: 27460974
Cancers (Basel). 2019 Apr 29;11(5):
pubmed: 31032816
Sci Transl Med. 2018 Jun 20;10(446):
pubmed: 29925635
Mol Cell. 2002 Sep;10(3):509-21
pubmed: 12408820
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Cancer Cell. 2018 Nov 12;34(5):807-822.e7
pubmed: 30423298
Genes Dev. 2003 Dec 15;17(24):3112-26
pubmed: 14681207
Immunity. 2001 Jan;14(1):45-55
pubmed: 11163229
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
Nature. 2005 Apr 7;434(7034):772-7
pubmed: 15800576
Cancer Res. 1999 Mar 15;59(6):1295-300
pubmed: 10096562
Sci Transl Med. 2018 Jun 20;10(446):
pubmed: 29925636
Cell Rep. 2017 Feb 21;18(8):1958-1969
pubmed: 28228261
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074
Genes Dev. 2000 Oct 1;14(19):2501-14
pubmed: 11018017

Auteurs

Nathiya Muthalagu (N)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Tiziana Monteverde (T)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Ximena Raffo-Iraolagoitia (X)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Robert Wiesheu (R)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Declan Whyte (D)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Ann Hedley (A)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Sarah Laing (S)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Björn Kruspig (B)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Rosanna Upstill-Goddard (R)

Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.

Robin Shaw (R)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Sarah Neidler (S)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Curtis Rink (C)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Saadia A Karim (SA)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Katarina Gyuraszova (K)

Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Colin Nixon (C)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

William Clark (W)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.

Andrew V Biankin (AV)

Wolfson Wohl Translational Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.

Leo M Carlin (LM)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Seth B Coffelt (SB)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Owen J Sansom (OJ)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Jennifer P Morton (JP)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom. daniel.murphy@glasgow.ac.uk Jennifer.morton@glasgow.ac.uk.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Daniel J Murphy (DJ)

CRUK Beatson Institute, Glasgow, Scotland, United Kingdom. daniel.murphy@glasgow.ac.uk Jennifer.morton@glasgow.ac.uk.
Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH